Mesoblast CEO Itescu exercises options, boosting stake to over 80.8 million shares
Silviu Itescu paid A$2,733,734 to exercise options, according to a company filing dated July 21, 2026.
Mesoblast Limited disclosed in a Form 6-K that Founder and Chief Executive Officer Dr. Silviu Itescu paid Mesoblast A$2,733,734 to exercise 1,885,334 options at a price of A$1.45 each.1 The announcement was dated July 20 in New York and July 21 in Melbourne, 2026.
Following the transaction, Dr. Itescu has not sold any of the newly acquired shares, and his total holding now stands at 80,844,262 shares of Mesoblast common stock.1
In the release, Dr. Itescu said the purchase reflected his view of the company's outlook, stating: "The investment reflects my strong confidence in Mesoblast's continued growth trajectory and its value proposition."1
The filing also included background on Mesoblast's business. The company describes itself as focused on developing off-the-shelf cell therapies made from mesenchymal lineage cells that work by responding to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, reducing the damaging inflammatory process.1 Its lead product, Ryoncil (remestemcel-L-rknd), is approved by the FDA for steroid-refractory acute graft versus host disease in pediatric patients age 2 months and older, marking it as the first FDA-approved mesenchymal stromal cell therapy.1
The company said it is pursuing additional uses of its cell therapy platforms, noting that Ryoncil is being studied for further inflammatory conditions, including the adult form of steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease, while its rexlemestrocel-L platform is in development for heart failure and chronic low back pain.1 Mesoblast also stated it has established commercial partnerships in Japan, Europe and China.1
The filing was signed by Company Secretary Niva Sivakumar on July 21, 2026, and referenced several related ASX filings issued the same day, including a new issue announcement and disclosures on director interests and share quotation.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.